Drugs in the making.com
Dr.Shruti Bhat, Leader Pharmaceutical R&D and Expert in hiTech formulation development for over 35 different therapeutic class of drugs moeities, brings to you some highlights from current pharma and clinical research news, views and data.
Presented below are updates in Pharmaceutical and clinical research-
Experimental Prostate Cancer Drug Combined With Prednisone/Prednisolone Appears To Reduce Mortality Risk.
Bloomberg News reported, "Sanofi-Aventis SA said new data from the late-stage Tropic trial showed that the experimental prostate cancer medicine cabazitaxel combined with prednisone/prednisolone reduced the risk of death by 28 percent, in an emailed statement today." In fact...
Drugmaker Proposing Shortened Research Path For Cholesterol Drug.
Bloomberg News reported that Karo Bio AB, "a Swedish pharmaceutical company with no products on the market," is currently "hatching a drug-testing shortcut to catapult its experimental cholesterol pill," called eprotirome, "into a potential $1.3 billion-a-year ...
FDA Warned At Least 43 Drug Plants In Recent Months Over Manufacturing Practices.
USA Today reported that, "At least 43 drug factories supplying medication to thousands of US consumers have received government warnings in recent months for failing to correct shoddy manufacturing practices that may have exposed patients to health risks...
Lamotrigine May Be Most Effective Antiepileptic Drug For Older Adults.
Medscape reported, "Lamotrigine is the most effective antiepileptic drug (AED) in older adults with epilepsy, with levetiracetam a close second, according to the results of a retrospective review of 10 AEDs reported in the April issue of the Archives of Neurology." The study compared ...
Investigational Drug May Suppress Appetite, Lower Blood Pressure.
WebMD reported that "an experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure...according to new research presented at ...
FDA Grants Orphan Drug Status To Potential Type-1 Diabetes Treatment.
Dow Jones Newswire reports that the FDA granted Osiris Therapeutics Inc. orphan-drug designation for its stem cell therapy Prochymal as a treatment for type-1 diabetes. The drug is currently in midstage trials, and Osiris is seeking approval for multiple indications.
Shingles Vaccine Appears To Be Well-Tolerated, But Not Widely Used.
MedPage Today reported, "The vaccine against shingles, already shown to be effective, is both safe and well-tolerated, researchers" at the Veterans Affairs New York Harbor Healthcare System "found ...
Vitamin A May Improve Response To Standard HCV Treatment.
MedPage Today reported, "Early and sustained virologic responses to standard treatment for hepatitis C virus (HCV) infection were markedly improved when patients also received high doses of vitamin A," according to a Japanese study that included 42 participants...
More at http://www.pharm-education.com/2010/05/pharmaceutical-r-updates-fda-grants.html
Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Expert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
YouTube Channel : Http://www.youtube.com/user/ShrutiBhat10
Note : Shruti has initiated a new blog Http://www.PharmaceuticalCareerDevelopment.blogspot.com which contains articles on motivation, career counselling and coaching, job search strategies, personal branding etc. especially for pharma professionals.
Do you have questions for the author?
Dr. Shruti U. Bhat
Pharmaceutical Manufacturing, Continuous Improvement and Business Transformation Consultant
New Release !
The information posted here, not limited to blogs, website, podcasts, videos, eBooks, whitepapers and other 'free' resources including downloaded items are Copyright protected, 'for review' purpose only. Not to be copied, distributed or used without prior written authorization by Dr. Shruti U. Bhat. Any instance(s) found to the contrary would be construed as copyright violation, illegal, plagiarism and/or could be subject to legal proceedings.
For additional details, refer our Terms & Conditions for site usage.
Kaizen book at # 4 on Amazon Best Sellers List!